AnaptysBio Inc - Asset Resilience Ratio
AnaptysBio Inc (ANAB) has an Asset Resilience Ratio of 20.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AnaptysBio Inc (ANAB) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how AnaptysBio Inc's Asset Resilience Ratio has changed over time. See net assets of AnaptysBio Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down AnaptysBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AnaptysBio Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $73.44 Million | 20.15% |
| Total Liquid Assets | $73.44 Million | 20.15% |
Asset Resilience Insights
- Good Liquidity Position: AnaptysBio Inc maintains a healthy 20.15% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
AnaptysBio Inc Industry Peers by Asset Resilience Ratio
Compare AnaptysBio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for AnaptysBio Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for AnaptysBio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.15% | $73.44 Million | $364.39 Million | -34.06pp |
| 2024-12-31 | 54.21% | $262.29 Million | $483.83 Million | -24.25pp |
| 2023-12-31 | 78.46% | $354.94 Million | $452.39 Million | +17.85pp |
| 2022-12-31 | 60.61% | $369.93 Million | $610.38 Million | +52.46pp |
| 2021-12-31 | 8.14% | $52.37 Million | $643.07 Million | -26.23pp |
| 2020-12-31 | 34.38% | $143.20 Million | $416.55 Million | -12.32pp |
| 2019-12-31 | 46.69% | $203.21 Million | $435.20 Million | -14.90pp |
| 2018-12-31 | 61.59% | $313.49 Million | $509.00 Million | +10.82pp |
| 2017-12-31 | 50.77% | $167.22 Million | $329.36 Million | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more